CEO’s Greetings

Welcome to CKD BiO.

We, CKD BiO, built nation’s largest API synthesis plant in 1965 and localized the production of antibiotic APIs such as Chloramphenicol and Tetracycline leading the early years of Korean pharmaceutical industry, through very own facility & technology. Since then, we put our efforts in localization and export of APIs, obtaining US FDA approval on Chloramphenicol for the first time in Korea in 1968.

To reinforce our global competitiveness via selection amp; concentration against the rapidly changing business environment, we have spun off from Chong Kun Dang Corp. in 2001. Ever since, we concentrated in expanding our R amp; D capability and product development, based on our world-class API fermentation, synthesis amp; biotechnologies. As a result, our Potassium Clavulanate, the β-lactamase inhibitor, was selected as the “Korean world-class Product for the next-generation” by the Ministry of Commerce, Industry and Energy in 2004.

In 2005, we were approved with “Certificate of Suitability” by EDQM (European Directorate for the Quality of Medicines), followed by “US FDA’s approval” in 2007 and other international authorities’ approvals for our various products. Based on approvals from global authorization and our reputation in global market, We are now exporting our products to more than 60 countries.

All of CKD BiO members promise to give our best for taking another big step as a global leader in the world API industry, through a series of facility investment and R&D, utilizing our technology & know-how accumulated over several decades.

Thank you.

CKD BiO Corporation
CEO
Wan-Kap, Park